Ken Griffin Charles River Laboratories International, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 83,000 shares of CRL stock, worth $17.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

83,000

Previous 43,600 90.37%

Holding current value

$17.1 Million

Previous $11.8 Million 45.15%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$206.39 - $268.73 $5.28 Million - $6.87 Million	25,578 Added 778.87%	28,862 $5.96 Million
Q1 2024 May 15, 2024	BUY	$203.52 - $273.43 $629,690 - $845,992	3,094 Added 1628.42%	3,284 $889,000
Q4 2023 Feb 14, 2024	SELL	$164.52 - $238.84 $1.03 Million - $1.5 Million	-6,280 Reduced 97.06%	190 $44,000
Q3 2023 Nov 14, 2023	SELL	$194.44 - $217.61 $3.93 Million - $4.4 Million	-20,200 Reduced 75.74%	6,470 $1.27 Million
Q2 2023 Aug 14, 2023	BUY	$183.71 - $210.25 $3.56 Million - $4.07 Million	19,370 Added 265.34%	26,670 $5.61 Million
Q1 2023 May 15, 2023	SELL	$191.89 - $259.92 $6.4 Million - $8.66 Million	-33,332 Reduced 82.03%	7,300 $1.47 Million
Q4 2022 Feb 14, 2023	BUY	$197.11 - $250.07 $4.4 Million - $5.58 Million	22,298 Added 121.62%	40,632 $8.85 Million
Q3 2022 Nov 14, 2022	BUY	$182.44 - $250.54 $463,944 - $637,123	2,543 Added 16.1%	18,334 $3.61 Million
Q2 2022 Aug 15, 2022	SELL	$204.13 - $302.4 $42.6 Million - $63.1 Million	-208,775 Reduced 92.97%	15,791 $3.38 Million
Q1 2022 May 16, 2022	BUY	$255.51 - $362.11 $6.19 Million - $8.77 Million	24,222 Added 12.09%	224,566 $63.8 Million
Q4 2021 Feb 14, 2022	BUY	$351.38 - $448.68 $12.6 Million - $16.1 Million	35,873 Added 21.81%	200,344 $75.5 Million
Q3 2021 Nov 15, 2021	SELL	$372.64 - $458.3 $39.3 Million - $48.3 Million	-105,336 Reduced 39.04%	164,471 $67.9 Million
Q2 2021 Aug 16, 2021	BUY	$294.17 - $371.65 $54.7 Million - $69.1 Million	185,911 Added 221.6%	269,807 $99.8 Million
Q1 2021 May 17, 2021	SELL	$249.67 - $299.48 $34.4 Million - $41.3 Million	-137,894 Reduced 62.17%	83,896 $24.3 Million
Q4 2020 Feb 16, 2021	BUY	$222.0 - $252.62 $38.1 Million - $43.3 Million	171,542 Added 341.39%	221,790 $55.4 Million
Q3 2020 Nov 16, 2020	SELL	$175.56 - $226.45 $26.7 Million - $34.4 Million	-152,079 Reduced 75.16%	50,248 $11.4 Million
Q2 2020 Aug 14, 2020	BUY	$118.84 - $189.72 $6.72 Million - $10.7 Million	56,556 Added 38.8%	202,327 $35.3 Million
Q1 2020 May 15, 2020	BUY	$98.9 - $178.34 $3.2 Million - $5.78 Million	32,398 Added 28.58%	145,771 $18.4 Million
Q4 2019 Feb 14, 2020	SELL	$126.05 - $152.76 $12.4 Million - $15 Million	-98,454 Reduced 46.48%	113,373 $17.3 Million
Q2 2019 Aug 14, 2019	BUY	$123.4 - $148.55 $25.7 Million - $30.9 Million	208,224 Added 5779.18%	211,827 $30.1 Million
Q1 2019 May 15, 2019	SELL	$104.82 - $146.73 $1.03 Million - $1.45 Million	-9,855 Reduced 73.23%	3,603 $0
Q4 2018 Feb 14, 2019	SELL	$105.09 - $137.23 $1.75 Million - $2.29 Million	-16,684 Reduced 55.35%	13,458 $1.52 Million
Q3 2018 Nov 13, 2018	BUY	$112.11 - $134.54 $2.9 Million - $3.48 Million	25,892 Added 609.22%	30,142 $0
Q2 2018 Aug 10, 2018	BUY	$102.37 - $117.25 $230,844 - $264,398	2,255 Added 113.03%	4,250 $0
Q1 2018 May 11, 2018	SELL	$98.19 - $115.2 $7.56 Million - $8.87 Million	-77,000 Reduced 97.47%	1,995 $213,000
Q4 2017 Feb 09, 2018	BUY	$100.43 - $118.09 $4.61 Million - $5.43 Million	45,952 Added 139.07%	78,995 $8.65 Million
Q3 2017 Nov 09, 2017	BUY	$96.72 - $109.26 $3.2 Million - $3.61 Million	33,043	33,043 $3.57 Million

Others Institutions Holding CRL

# of Institutions

712

Shares Held

49.8M

Call Options Held

208K

Put Options Held

236K

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $10.5B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account